个人中心 - 老虎社区

oyzheng

IP属地：未知

帖子 · 15帖子 · 15
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- oyzhengoyzheng
  ·2021-06-15
  Looks good
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
  It was "better late than never" for Novavax, Inc.NVAX, as the biopharma finally got around to announ
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
  866 评论
  2
  分享
  举报
- oyzhengoyzheng
  ·2021-06-15
  Nice
  非常抱歉，此主贴已删除
  870 评论
  1
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Good read
  非常抱歉，此主贴已删除
  769 评论
  2
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Oh no!
  非常抱歉，此主贴已删除
  1,138 评论
  1
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Good info
  PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments
  Summary PayPal is a leading fintech company that benefits immensely from the secular growth trend i
  PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments
  607 评论
  点赞
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Nice
  非常抱歉，此主贴已删除
  1,195 评论
  1
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  I agree
  非常抱歉，此主贴已删除
  1,825 评论
  5
  分享
  举报
- oyzhengoyzheng
  ·2021-06-12
  Interesting
  非常抱歉，此主贴已删除
  592 评论
  点赞
  分享
  举报
- oyzhengoyzheng
  ·2021-06-12
  Oh no
  非常抱歉，此主贴已删除
  1,776 评论
  点赞
  分享
  举报
- oyzhengoyzheng
  ·2021-06-12
  Good info
  非常抱歉，此主贴已删除
  1,989 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575704006877751","uuid":"3575704006877751","gmtCreate":1612612352712,"gmtModify":1612612352712,"name":"oyzheng","pinyin":"oyzheng","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.28","exceedPercentage":"60.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.38%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":187654423,"gmtCreate":1623753263762,"gmtModify":1634029019236,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Looks good","listText":"Looks good","text":"Looks good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187654423","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187656147,"gmtCreate":1623753166989,"gmtModify":1634029022357,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187656147","repostId":"1142697857","repostType":4,"isVote":1,"tweetType":1,"viewCount":870,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185214446,"gmtCreate":1623652948485,"gmtModify":1634030606220,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185214446","repostId":"2143785982","repostType":4,"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185214225,"gmtCreate":1623652934867,"gmtModify":1634030606466,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Oh no!","listText":"Oh no!","text":"Oh no!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185214225","repostId":"2143789794","repostType":4,"isVote":1,"tweetType":1,"viewCount":1138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185214328,"gmtCreate":1623652907864,"gmtModify":1634030606812,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Good info","listText":"Good info","text":"Good info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185214328","repostId":"1141995531","repostType":4,"repost":{"id":"1141995531","kind":"news","pubTimestamp":1623652578,"share":"https://www.laohu8.com/m/news/1141995531?lang=&edition=full","pubTime":"2021-06-14 14:36","market":"us","language":"en","title":"PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=1141995531","media":"seekingalpha","summary":"Summary\n\nPayPal is a leading fintech company that benefits immensely from the secular growth trend i","content":"<p><b>Summary</b></p>\n<ul>\n <li>PayPal is a leading fintech company that benefits immensely from the secular growth trend in the digital payments industry.</li>\n <li>Its growth history is impressive and momentum is not showing any sign of slowing down, making its 2025 targets quite achievable.</li>\n <li>The premium valuation to Visa or Mastercard is justified and PayPal is now my largest holding in the digital payments theme.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa4976c13e5ffab4c5035b08d60831ed\" tg-width=\"768\" tg-height=\"512\"><span>JasonDoiy/iStock Unreleased via Getty Images</span></p>\n<p><b>PayPal</b>(PYPL) is a compelling long-term play on the secular growth trend of digital payments as the company’s growth path is likely to remain quite strong over the next few years.</p>\n<p><b>Company Profile</b></p>\n<p>PayPal Holdings Inc. is a leading fintech company that enables digital and mobile payments through its technology platform. Its major competitors are other payment technology companies, such as<b>Visa</b>(V),<b>Mastercard</b>(MA) or<b>Adyen</b>(OTCPK:ADYEY). It currently has a market capitalization of about $309 billion, a smaller value than MasterCard or Visa.</p>\n<p>PayPal’s core business is the offering of payment solutions to merchants and consumers, operating globally. At the end of 2020, it had about 377 million active accounts, of which some 348 million consumer accounts and 29 million merchant accounts, more than double the number of active accounts at the end of 2015.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/45f478cd622b0c634fd146fdf46bf0ef\" tg-width=\"747\" tg-height=\"432\"><span>Source: PayPal.</span></p>\n<p>The company’s revenue stream comes mainly from charging fees for some completed payment transactions, while generally it does not charge consumers to fund or withdraw money from their PayPal account. It also generates revenues from currency conversion and instant transfers from the PayPal or Venmo accounts to debit cards or bank accounts. For its merchant clients, it also offers access to certain credit products for small and medium-sized merchants, increasing its engagement its clients and providing finance for clients that possibly would not get loans from traditional banks or other lending providers.</p>\n<p><b>Secular Growth</b></p>\n<p>As I’ve analyzed in a previous article on “Visa: Despite Earnings Dip, Secular Growth Prospects Remain Strong,” the global payments industry has a very good growth track record and future growth prospects are quite strong.</p>\n<p>During the past few years, consumers and businesses have increasingly adopted new payment methods beyond cash and the rise of e-commerce has also been an important growth driver of digital payments across the globe. Revenues for the industry have grown roughly at 7% per year over recent years, to a total of just under $2 trillion in 2019, according to McKinsey data, and this growth is only expected to accelerate in the future as digital payments continue to increase their market share as a percentage of total banking revenues.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d27b37a2ed30f39bff844ae07aa49ac5\" tg-width=\"372\" tg-height=\"395\"><span>Source: McKinsey.</span></p>\n<p>This background has been very supportive for PayPal’s growth prospects, as one of the leading companies in this industry. Indeed, PayPal’s revenues have increased at a compounded annual growth rate [CAGR] of 20.8% during the past five years, a much higher growth rate than the global payments industry and also above its largest competitors like Visa and MasterCard.</p>\n<p>Moreover, while recently the growth path of digital payments has changed due to the coronavirus pandemic, that has affected negatively the growth of the global payments industry, PayPal has remained on a strong growth path because its business is clearly more exposed to digital transactions rather than physical payments. This means that the pandemic has barely impacted its business, while it has been a significant setback for other companies, such as&nbsp;<b>American Express</b>&nbsp;(AXP) or MasterCard that are more exposed to cross-border transactions.</p>\n<p>Nevertheless, the Covid-19 seems to be positive for the long-term growth of the industry because digital payments became more adopted last year and people will likely use less cash for payment transactions in the future, accelerating even further the growth of digital payments across the world.</p>\n<p>Over the next few years, growth is expected to resume quite rapidly and should even be higher than in the recent past. According to Mordor Intelligence, the global digital payments industry is expected to have a revenue CAGR of 13.7% during 2021-26, which is almost double the growth in recent years. This clearly shows that digital payments is a secular growth industry, being a very good backdrop for the companies operating in this industry for years to come.</p>\n<p>Taking this environment into account, PayPal is clearly in a very good position to maintain a solid growth path for many years to come, being potentially one of the major winners of the global shift to digital payments and e-commerce.</p>\n<p>Taking this background into account, it is not surprising that PayPal has strong growth ambitions for the coming years, aiming to generate more than $50 billion in revenue by 2025 (more than double the 2020 revenues) both from growth of its existing business, higher customer engagement and new offerings that will increase PayPal’s total addressable market.</p>\n<p>PayPal expects to double the number of active accounts over the next five years and triple the volumes transacted, which seems to be achievable considering its growth history and the strong growth prospects of the global payments industry.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/828bae36490c031b69fcf87de3ef91a8\" tg-width=\"640\" tg-height=\"341\"><span>Source: PayPal.</span></p>\n<p>This means that $50 billion in revenue by 2025 represents CAGR of about 20% during 2020-25, showing that PayPal has very good growth prospects in coming years. Moreover, as the company expects to improve a little bit its business margins during this period, its earnings are expected to increase at CAGR of 22% over the next five years and generate more than $40 billion in free cash flow.</p>\n<p><b>Financial Overview</b></p>\n<p>Regarding its financial performance, PayPal has a very good track record with revenues and earnings growing quite rapidly over the past few years. Indeed, from 201 to 2020, PayPal’s revenues increased at a CAGR of around 20% and its earnings increased at CAGR of 31%, a very impressive achievement and much better than established peers like Visa and MasterCard.</p>\n<p>More recently, the company’s growth was not interrupted by the coronavirus as the secular growth trends of e-commerce and cash displacement accelerated with the pandemic, being a very strong tailwind for the company’s growth.</p>\n<p>In 2020, PayPal recorded record financial figures regarding its revenues, volumes, net new active accounts and earnings. Indeed, PayPal’s revenues increased by 20.8% YoY to $21.5 billion, a level that is very close to Visa’s annual revenues showing that PayPal has achieved a very large size despite being a much younger company. Beyond higher revenues, its business margins and free cash flow generation also improved, a very good performance compared to its peers that rely more on debit and credit card payments.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6b1369e32917090ea7cdb92b9a2fe8a\" tg-width=\"772\" tg-height=\"359\"><span>Source: PayPal.</span></p>\n<p>This positive financial performance was justified by the shift to online shopping and transactions due to Covid-19, but also due to PayPal’s new offerings such as the option to buy and hold digital currencies during the last quarter of the year. Its net income amounted to $4.2 billion, an increase of 70% YoY, boosted by organic growth and gains on some investments and its free cash flow was about $5 billion, or 23% of revenue, which shows that PayPal has a very good cash flow generation capacity.</p>\n<p>During thefirst quarter of 2021, PayPal has maintained an impressive operating momentum with volumes up by 50% YoY and revenue up by 31% YoY. Active accounts grew by 21% to 392 million, while it added 14.5 million net new accounts during the quarter. Its operating margin improved to 27.7% (non-GAAP) and non-GAAP EPS grew by 84% YoY and free cash flow amounted to $1.54 billion or 25% of its quarterly revenue.</p>\n<p>For the full year 2021, its guidance was revised upwards with Q1 earnings and PayPal now expects to grow revenues to about $25.7 billion, which represents annual growth of about 20% in constant currencies, EPS growth around 21% YoY and about $6 billion in free cash flow.</p>\n<p>This clearly shows that PayPal’s growth momentum is not showing any sign of slowdown over the coming quarters, boding quite well to reach its 2025 targets probably ahead of schedule if it continues to grow at this pace.</p>\n<p>However, this is not currently expected from the sell-side, given that according toanalysts’ estimates, revenue growth is expected to be around 20-21% during the next 2-3 years and then slow down a little bit to less than 20% in 2024 and 2025. This is in-line with PayPal’s own targets, which means that there is some potential upside to estimates if it continues to execute well on its growth initiatives during the next few years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9ee830ca42c6ed20907df39e8c28786b\" tg-width=\"902\" tg-height=\"250\"><span>Source: SeekingAlpha.</span></p>\n<p>Regarding its capital allocation, PayPal’s has used its cash flow generation capacity to finance several acquisitions and repurchase its own shares, while capex spending has been relatively limited as expected for a technology company that operates digitally. Going forward, this strategy is not expected to change much as PayPal should continue to invest in fintech innovation through PayPal Ventures, while share buybacks will be the main way to return capital to shareholders even though the company may decide to start distributing dividends in the coming years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/530c58f1461ce1f7eefb7856a4ef2d05\" tg-width=\"563\" tg-height=\"318\"><span>Source: PayPal.</span></p>\n<p><b>Conclusion</b></p>\n<p>PayPal has a very good business and its growth prospects are very strong, both from industry tailwinds and its own growth initiatives. I think this is one of the best ways to play the secular growth trend of digital payments, as PayPal’s business model is completely focused on digital channels while its closest competitors Visa or Mastercard still rely significantly in physical transactions.</p>\n<p>This profile justifies PayPal’s premium valuation, considering that it is currentlytrading at about 57x forward earnings, while Visa and Mastercard are trading at between 42-47x earnings. Regarding my personal portfolio, I’ve recently rebalanced my positions and PayPal is now my largest holding on the digital payments theme, as I see this company as a very compelling long-term play in this industry.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 14:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434455-paypal-best-play-on-secular-growth-trend-of-digital-payments><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPayPal is a leading fintech company that benefits immensely from the secular growth trend in the digital payments industry.\nIts growth history is impressive and momentum is not showing any ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434455-paypal-best-play-on-secular-growth-trend-of-digital-payments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PYPL":"PayPal"},"source_url":"https://seekingalpha.com/article/4434455-paypal-best-play-on-secular-growth-trend-of-digital-payments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141995531","content_text":"Summary\n\nPayPal is a leading fintech company that benefits immensely from the secular growth trend in the digital payments industry.\nIts growth history is impressive and momentum is not showing any sign of slowing down, making its 2025 targets quite achievable.\nThe premium valuation to Visa or Mastercard is justified and PayPal is now my largest holding in the digital payments theme.\n\nJasonDoiy/iStock Unreleased via Getty Images\nPayPal(PYPL) is a compelling long-term play on the secular growth trend of digital payments as the company’s growth path is likely to remain quite strong over the next few years.\nCompany Profile\nPayPal Holdings Inc. is a leading fintech company that enables digital and mobile payments through its technology platform. Its major competitors are other payment technology companies, such asVisa(V),Mastercard(MA) orAdyen(OTCPK:ADYEY). It currently has a market capitalization of about $309 billion, a smaller value than MasterCard or Visa.\nPayPal’s core business is the offering of payment solutions to merchants and consumers, operating globally. At the end of 2020, it had about 377 million active accounts, of which some 348 million consumer accounts and 29 million merchant accounts, more than double the number of active accounts at the end of 2015.\nSource: PayPal.\nThe company’s revenue stream comes mainly from charging fees for some completed payment transactions, while generally it does not charge consumers to fund or withdraw money from their PayPal account. It also generates revenues from currency conversion and instant transfers from the PayPal or Venmo accounts to debit cards or bank accounts. For its merchant clients, it also offers access to certain credit products for small and medium-sized merchants, increasing its engagement its clients and providing finance for clients that possibly would not get loans from traditional banks or other lending providers.\nSecular Growth\nAs I’ve analyzed in a previous article on “Visa: Despite Earnings Dip, Secular Growth Prospects Remain Strong,” the global payments industry has a very good growth track record and future growth prospects are quite strong.\nDuring the past few years, consumers and businesses have increasingly adopted new payment methods beyond cash and the rise of e-commerce has also been an important growth driver of digital payments across the globe. Revenues for the industry have grown roughly at 7% per year over recent years, to a total of just under $2 trillion in 2019, according to McKinsey data, and this growth is only expected to accelerate in the future as digital payments continue to increase their market share as a percentage of total banking revenues.\nSource: McKinsey.\nThis background has been very supportive for PayPal’s growth prospects, as one of the leading companies in this industry. Indeed, PayPal’s revenues have increased at a compounded annual growth rate [CAGR] of 20.8% during the past five years, a much higher growth rate than the global payments industry and also above its largest competitors like Visa and MasterCard.\nMoreover, while recently the growth path of digital payments has changed due to the coronavirus pandemic, that has affected negatively the growth of the global payments industry, PayPal has remained on a strong growth path because its business is clearly more exposed to digital transactions rather than physical payments. This means that the pandemic has barely impacted its business, while it has been a significant setback for other companies, such as American Express (AXP) or MasterCard that are more exposed to cross-border transactions.\nNevertheless, the Covid-19 seems to be positive for the long-term growth of the industry because digital payments became more adopted last year and people will likely use less cash for payment transactions in the future, accelerating even further the growth of digital payments across the world.\nOver the next few years, growth is expected to resume quite rapidly and should even be higher than in the recent past. According to Mordor Intelligence, the global digital payments industry is expected to have a revenue CAGR of 13.7% during 2021-26, which is almost double the growth in recent years. This clearly shows that digital payments is a secular growth industry, being a very good backdrop for the companies operating in this industry for years to come.\nTaking this environment into account, PayPal is clearly in a very good position to maintain a solid growth path for many years to come, being potentially one of the major winners of the global shift to digital payments and e-commerce.\nTaking this background into account, it is not surprising that PayPal has strong growth ambitions for the coming years, aiming to generate more than $50 billion in revenue by 2025 (more than double the 2020 revenues) both from growth of its existing business, higher customer engagement and new offerings that will increase PayPal’s total addressable market.\nPayPal expects to double the number of active accounts over the next five years and triple the volumes transacted, which seems to be achievable considering its growth history and the strong growth prospects of the global payments industry.\nSource: PayPal.\nThis means that $50 billion in revenue by 2025 represents CAGR of about 20% during 2020-25, showing that PayPal has very good growth prospects in coming years. Moreover, as the company expects to improve a little bit its business margins during this period, its earnings are expected to increase at CAGR of 22% over the next five years and generate more than $40 billion in free cash flow.\nFinancial Overview\nRegarding its financial performance, PayPal has a very good track record with revenues and earnings growing quite rapidly over the past few years. Indeed, from 201 to 2020, PayPal’s revenues increased at a CAGR of around 20% and its earnings increased at CAGR of 31%, a very impressive achievement and much better than established peers like Visa and MasterCard.\nMore recently, the company’s growth was not interrupted by the coronavirus as the secular growth trends of e-commerce and cash displacement accelerated with the pandemic, being a very strong tailwind for the company’s growth.\nIn 2020, PayPal recorded record financial figures regarding its revenues, volumes, net new active accounts and earnings. Indeed, PayPal’s revenues increased by 20.8% YoY to $21.5 billion, a level that is very close to Visa’s annual revenues showing that PayPal has achieved a very large size despite being a much younger company. Beyond higher revenues, its business margins and free cash flow generation also improved, a very good performance compared to its peers that rely more on debit and credit card payments.\nSource: PayPal.\nThis positive financial performance was justified by the shift to online shopping and transactions due to Covid-19, but also due to PayPal’s new offerings such as the option to buy and hold digital currencies during the last quarter of the year. Its net income amounted to $4.2 billion, an increase of 70% YoY, boosted by organic growth and gains on some investments and its free cash flow was about $5 billion, or 23% of revenue, which shows that PayPal has a very good cash flow generation capacity.\nDuring thefirst quarter of 2021, PayPal has maintained an impressive operating momentum with volumes up by 50% YoY and revenue up by 31% YoY. Active accounts grew by 21% to 392 million, while it added 14.5 million net new accounts during the quarter. Its operating margin improved to 27.7% (non-GAAP) and non-GAAP EPS grew by 84% YoY and free cash flow amounted to $1.54 billion or 25% of its quarterly revenue.\nFor the full year 2021, its guidance was revised upwards with Q1 earnings and PayPal now expects to grow revenues to about $25.7 billion, which represents annual growth of about 20% in constant currencies, EPS growth around 21% YoY and about $6 billion in free cash flow.\nThis clearly shows that PayPal’s growth momentum is not showing any sign of slowdown over the coming quarters, boding quite well to reach its 2025 targets probably ahead of schedule if it continues to grow at this pace.\nHowever, this is not currently expected from the sell-side, given that according toanalysts’ estimates, revenue growth is expected to be around 20-21% during the next 2-3 years and then slow down a little bit to less than 20% in 2024 and 2025. This is in-line with PayPal’s own targets, which means that there is some potential upside to estimates if it continues to execute well on its growth initiatives during the next few years.\nSource: SeekingAlpha.\nRegarding its capital allocation, PayPal’s has used its cash flow generation capacity to finance several acquisitions and repurchase its own shares, while capex spending has been relatively limited as expected for a technology company that operates digitally. Going forward, this strategy is not expected to change much as PayPal should continue to invest in fintech innovation through PayPal Ventures, while share buybacks will be the main way to return capital to shareholders even though the company may decide to start distributing dividends in the coming years.\nSource: PayPal.\nConclusion\nPayPal has a very good business and its growth prospects are very strong, both from industry tailwinds and its own growth initiatives. I think this is one of the best ways to play the secular growth trend of digital payments, as PayPal’s business model is completely focused on digital channels while its closest competitors Visa or Mastercard still rely significantly in physical transactions.\nThis profile justifies PayPal’s premium valuation, considering that it is currentlytrading at about 57x forward earnings, while Visa and Mastercard are trading at between 42-47x earnings. Regarding my personal portfolio, I’ve recently rebalanced my positions and PayPal is now my largest holding on the digital payments theme, as I see this company as a very compelling long-term play in this industry.","news_type":1,"symbols_score_info":{"PYPL":0.9}},"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185215445,"gmtCreate":1623652885087,"gmtModify":1634030607279,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185215445","repostId":"1146430910","repostType":4,"isVote":1,"tweetType":1,"viewCount":1195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185215546,"gmtCreate":1623652860685,"gmtModify":1634030607401,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"I agree","listText":"I agree","text":"I agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185215546","repostId":"1165811803","repostType":4,"isVote":1,"tweetType":1,"viewCount":1825,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186974421,"gmtCreate":1623471511163,"gmtModify":1634032682652,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/186974421","repostId":"2142744202","repostType":4,"isVote":1,"tweetType":1,"viewCount":592,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186978096,"gmtCreate":1623471276015,"gmtModify":1634032686910,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/186978096","repostId":"2142202662","repostType":4,"isVote":1,"tweetType":1,"viewCount":1776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186971956,"gmtCreate":1623471250975,"gmtModify":1634032687856,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575704006877751","authorIdStr":"3575704006877751"},"themes":[],"htmlText":"Good info","listText":"Good info","text":"Good info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/186971956","repostId":"1177806573","repostType":4,"isVote":1,"tweetType":1,"viewCount":1989,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}